EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

Amatzia Gantz iD, Audrey Kapelanski-Lamoureux iD, Miran Rada iD, Lucyna Krzywon iD, Migmar Tsamchoe iD, Anastasia Tsatoumas iD, Stephanie K Petrillo iD, Nabil G Seidah iD, Anthoula Lazaris iD, Peter Metrakos iD

The FEBS Journal · 2026

DOI: 10.1111/febs.70348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Amatzia Gantz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department Anatomy and Cell Biology, McGill University, Quebec, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Cholesterol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholesterol availability has been implicated in cancer progression. Here, we demonstrate the connection between blood cholesterol concentration, the development of distinct histopathological growth patterns (HGPs) in colorectal cancer liver metastases (CRCLM), and new avenues of treatment for patients. Our study reveals that serum cholesterol levels correlate with the different HGPs, and patients on statins had desmoplastic HGPs and improved overall survival. We also demonstrate, in an in vivo mouse model, that inhibition of key modulators of cholesterol metabolism, using antiproprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, attenuated the development of CRCLM tumors, as well as the formation of vessel co‐opting lesions. Our findings underscore the importance of cholesterol in CRCLM and the potential clinical application of evolocumab to mitigate the growth of these histological types of tumors in CRCLM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsCholesterolAnimalsHumansMiceMaleFemaleAntibodies, Monoclonal, HumanizedPCSK9 InhibitorsProprotein Convertase 9

Stichwörter der Autor:innen

PCSK9angiogenesischolesterolsex stratificationvessel co‐option

Substanzen

CholesterolAntibodies, Monoclonal, HumanizedPCSK9 InhibitorsProprotein Convertase 9PCSK9 protein, human

Autor:innen und Institutionen

  • Department Anatomy and Cell Biology, McGill University, Quebec, Canada.
  • Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Canada.
  • Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Canada.

ORCID-Profile: Amatzia Gantz, Audrey Kapelanski-Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K Petrillo, Nabil G Seidah, Anthoula Lazaris, Peter Metrakos

Zitieren

APA

Gantz, A., Kapelanski-Lamoureux, A., Rada, M., Krzywon, L., Tsamchoe, M., Tsatoumas, A., Petrillo, S. K., Seidah, N. G., Lazaris, A., & Metrakos, P. (2026). High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases. The FEBS Journal. https://doi.org/10.1111/febs.70348

Vancouver

Gantz A, Kapelanski-Lamoureux A, Rada M, Krzywon L, Tsamchoe M, Tsatoumas A, et al. High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases. The FEBS Journal. 2026. doi:10.1111/febs.70348

BibTeX
@article{Gantz2026,
  author = {Gantz, Amatzia and Kapelanski-Lamoureux, Audrey and Rada, Miran and Krzywon, Lucyna and Tsamchoe, Migmar and Tsatoumas, Anastasia and Petrillo, Stephanie K and Seidah, Nabil G and Lazaris, Anthoula and Metrakos, Peter},
  title = {High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70348}
}
Kostenlos starten →